Skip to main content

Clinical Trials Using Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells

Review the clinical trials studying allogeneic cd34-positive enriched peripheral blood stem cells on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-4 of 4

Immunosuppression-Free Regulatory T Cell Graft-Engineered Haploidentical Donor Stem Cell Transplant for the Treatment of Relapsed/Refractory or Ultra High Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 3 locations
Specialized Stem Cell Transplant Product (CD34+ Selected Donor Cells) for the Treatment of Low Blood Counts after Donor Stem Cell Transplant
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Infusion of Conventional and Regulatory T-Cells for the Treatment of Patients with Hematologic Malignancies Undergoing Reduced Intensity Donor Stem Cell Transplant
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Selection of CD34 Positive Stem Cells using CliniMACS Prodigy Device for the Prevention of Graft-versus-Host Disease
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama